Alkermes plc Stock
Price
Target price
€48.22
€48.22
4.350%
2.01
4.350%
€47.71
26.06.26 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
Alkermes plc dominated the market today, gaining €2.01 (4.350%).
With 22 Buy predictions and not a single Sell prediction Alkermes plc is an absolute favorite of our community.
On the other hand, the target price of 47 € is below the current price of 48.22 € for Alkermes plc, so the potential is actually -2.53%.
Pros and Cons of Alkermes plc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | 4.350% | 24.471% | 49.011% | 97.623% | 104.322% | 61.812% | 138.713% |
| Icon plc | -0.270% | 19.831% | 46.539% | 20.850% | -3.679% | -28.554% | - |
| United Therapeutics | 2.120% | 2.430% | -4.242% | 96.251% | 11.467% | 142.762% | 215.430% |
| Ligand Pharmaceuticals | 0.770% | 10.833% | 30.392% | 172.821% | 60.241% | 300.000% | 128.228% |
Comments
Alkermes (ALKS) had its price target raised by Needham & Company LLC from $54.00 to $61.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "buy" rating reaffirmed by TD Cowen.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Needham & Company LLC from $50.00 to $54.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes’ lead orexin agonist, alixorexton, has entered Phase 3 with the Brilliance program now enrolling in
